Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)

Expert Review of Clinical Pharmacology

Volumn 9, Issue 6, 2016, Pages 755-770

  Mitchell, William M ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Ampligen; chronic fatigue myalgic encephalomyelitis; clinical efficacy; clinical safety; clinical trials; dsRNA; primate non primate disassociation of toxicity; Rintatolimod; TLR3 agonist

Indexed keywords

MYELOID DIFFERENTIATION FACTOR 88; RINTATOLIMOD; TOLL LIKE RECEPTOR 3; DOUBLE STRANDED RNA; POLY(I).POLY(C12,U); POLYINOSINIC POLYCYTIDYLIC ACID; POLYURIDYLIC ACID;

AREA UNDER THE CURVE; ARTICLE; CANINE MODEL; CHILL; CHRONIC FATIGUE SYNDROME; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTROL; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EAR DISEASE; ELIMINATION HALF-LIFE; FAINTNESS; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INJECTION SITE REACTION; MACACA FASCICULARIS; MAXIMUM PLASMA CONCENTRATION; MEDICINAL CHEMISTRY; MIGRAINE; MULTICENTER STUDY (TOPIC); NAUSEA; NEUROPATHOLOGY; NONHUMAN; PAIN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RABBIT MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAT MODEL; SIDE EFFECT; VASODILATATION; AGONISTS; ANIMAL; FATIGUE SYNDROME, CHRONIC; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; FATIGUE SYNDROME, CHRONIC; HUMANS; IMMUNITY, INNATE; POLY I-C; POLY U; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RNA, DOUBLE-STRANDED; TOLL-LIKE RECEPTOR 3;

EID: 84975105751     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1172960     Document Type: Article

References (97)

1. S.Johnston, E.W.Brenu, D.R.Staines, et al. The adoption of chronic fatigue syndrome/myalgic encephalomyelitis case definitions to assess prevalence: a systematic review. Ann Epidemiol. 2013;23:371–376.
2. L.A.Jason, M.C.Benton, L.Valentine, et al. The economic impact of ME/CFS: individual and societal costs. Dyn Med. 2008;7:6. doi:10.1186/1476-5918-7-6.
3. L.A.Jason, K.Corradi, S.Gress, et al. Causes of death among patients with chronic fatigue syndrome. Health Care Women Int. 2006;27:615–626.
4. A.L.Komaroff, D.S.Buchwald Chronic fatigue syndrome: an update. Annu Rev Med. 1998;49:1–13.
5. A.L.Komaroff. Is human herpesvirus-6 a trigger for chronic fatigue syndrome? J Clin Virol. 2006;37(Suppl 1):S39–S46.
6. N.Afari, D.Buchwald. Chronic fatigue syndrome: a review. Am J Psychiatry. 2003;60:221–236.
7. B.Poeschla, E.Strachan, E.Dansie, et al. Chronic fatigue and personality: a twin study of causal pathways and shared liabilities. Ann Behav Med. 2013;45:289–298.
8. L.D.Devanur, J.R.Kerr. Chronic fatigue syndrome. J Clin Virol. 2006;37:139–150.
9. J.R.Kerr, R.Petty, B.Burke, et al. Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Infect Dis. 2008;197:1171–1184.•• Establishes CSF/ME subtypes on the basis of differential gene expression profiles distinct from normal subjects.
10. J.R.Kerr, B.Burke, R.Petty, et al. Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol. 2008;61:730–739.
11. M.Hornig, J.G.Montoya, N.G.Klimas, et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv. 2015 Feb;1(1):e1400121.
12. [cited 2015 Dec 21]. Available from: http://www.nytimes.com/health/guides/disease/chronic-fatigue-syndrome/medications.html
13. P.O.Ts’o, J.L.Alderfer, J.Levy, et al. An integrated and comparative study of the antiviral effects and other biological properties of the polyinosinic acid-polycytidylic acid and its mismatched analogues. Mol Pharmacol. 1976;12:299–312.
14. L.Alexopoulou, A.C.Holt, R.Medzhitov, et al. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature. 2001;413:732–738.• Discovery of dsRNA as a TLR3 agonist.
15. A.Iwasaki, R.Medzhitov. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5:987–995.
16. J.Banchereau, R.M.Steinman. Dendritic cells and the control of immunity. Nature. 1998;392:245–252.
17. A.Bagchi, E.A.Herrup, H.S.Warren, et al. MyD88-dependent and myD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol. 2007;178:1164–1171.
18. B.B.Gowen, M.H.Wong, K.H.Jung, et al. TLR3 is essential for the induction of protective immunity against punta toro virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not poly(I:C): differential recognition of synthetic dsRNA molecules. J Immunol. 2007;178:5200–5208.•• First demonstration that rintatolimod in the induction of innate immunity is restricted to its activity as a TLR3 ligand.
19. C.Trumpfheller, M.Caskey, G.Nchinda, et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA. 2008;105:2574–2579.
20. W.M.Mitchell, C.F.Nicodemus, W.A.Carter, et al. Discordant biological and toxicological species responses to TLR3 activation. Am J Path. 2014;184:1062–1072.•• Demonstration of low systemic inflammatory cytokines following rintatolimod infusion. Demonstration of relative lack of rintatolimod toxicity in primates compared to lower order vertebrates (rodents, dogs, and rabbits).
21. [cited 2015 Oct 4]. Available from: http://www.nytimes.com/ref/health/healthguide/esn-chronicfatigue-ess.html
22. [cited 2015 Oct 4]. Available from: http://blogs.fda.gov/fdavoice/index.php/2013/06/fdas-latest-efforts-in-patient-focused-drug-development-now-in-full-swing/
23. I.E.Salit. Precipitating factors for the chronic fatigue syndrome. J Psychiatr Res. 1997;31:59–65.
24. D.R.Strayer, W.A.Carter, I.Brodsky, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis. 1994;18(Suppl 1):S88–S95.• Rintatolimod Phase II clinical trial.
25. 12U) in humans after intravenous infusion [Ph.D. thesis]. Philadelphia (PA): Hahnemann University; 1991.
26. 12U),mismatched double-stranded RNA, by rapid solution hybridization: blood values after intravenous infusion. J Pharm Pharmacol. 1990;42:261–266.
27. J.N.Leonard, R.Ghirlando, J.Askins, et al. The TLR3 signaling complex forms by cooperative receptor dimerization. Proc Natl Acad Sci U S A. 2008;105:258–263.
28. Y.Wang, L.Liu, D.R.Davies, et al. Dimerization of toll-like receptor 3 (TLR3) is required for ligand binding. J Biol Chem. 2010;285:36836–36841.• Molecular dynamics of TLR3 function.
29. M.R.Thompson, J.J.Kaminski, E.A.Kurt-Jones, et al. Pattern recognition receptors and the innate immune response to viral infection. Viruses. 2011;3:920–940.
30. M.Muzio, D.Bosisio, N.Polentarutti, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol. 2000;164:5998–6004.
31. M.E.Kleinman. iRNA via TLR3. Nature. 2008;452:591–597.
32. M.Yu. Levine SJ.Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses. Cytokine Growth Factor Rev. 2011;22:63–72.
33. J.Pohar, N.Pirher, M.Benčina, et al. The role of UNC93B1 protein in surface localization of TLR3 receptor and in cell priming to nucleic acid agonists. J Biol Chem. 2013;288:442–454.• Mechanism for TLR3 expression on the plasma membrane.
34. G.Geiss, G.Jin, J.Guo, et al. A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling. J Biol Chem. 2001;276:30178–30182.• First demonstration of the transient effect of gene transcription by activation of TLR3.
35. J.Luo, G.Obmolova, T.J.Malia, et al. Lateral clustering of TLR3: dsRNAsignaling units revealed by TLR3ecd:3Fabs quaternary structure. J Mol Biol. 2012;421:112–124.
36. I.Jelinek, J.N.Leonard, G.E.Price, et al. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol. 2011;186:2422–2429.
37. G.P.Holmes, J.E.Kaplan, N.M.Gantz, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med. 1988;108:387–389.• Initial CDC clinical definition of CFS. Although many refinements have been proposed and adopted since this description, all clinical studies with rintatolimod have used this initial definition in order to provide consistency between the studies.
38. K.Fukuda, S.E.Straus, I.Hickie, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121:953–959.
39. B.M.Carruthers, M.I.van de Sande, K.L.de Meirleir, et al. Myalgic encephalomyelitis: international consensus criteria. J Intern Med. 2011;270:327–338.
40. E.W.Clayton. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA. 2015;313:1101–1102.
41. D.R.Strayer, W.Carter, K.I.Strauss, et al. Long term improvements in patients with chronic fatigue syndrome treated with ampligen. J Chronic Fatigue Syn. 1995;1:35–53.
42. Current Hemispherx Biopharma NDA submission documents.
43. D.R.Strayer, W.A.Carter, B.C.Stouch, et al. A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One. 2012;7(3):e31334. doi:10.1371/journal.pone.0031334• Rintatolimod Phase III clinical trial.
44. D.R.Strayer, B.C.Stouch, S.R.Stevens, et.al. Chronic fatigue syndrome/ myalgic encephalomyelitis (CFS/ME): characteristics of responders to rintatolimod. J Drug Res Dev. 2015;1. doi:http://dx.doiorg/10.16966/jdrd.103.
45. J.M.Vanness, C.R.Snell, D.M.Fredrickson, et al. Assessment of functional impairment by cardiopulmonary exercise testing in patients with chronic fatigue syndrome. J Chronic Fatigue Syndrome. 2001;8:103–109.
46. S.E.Schutzer, T.E.Angel, T.Liu, et al. Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome. PLoS One. 2011 Feb 23;6(2):e17287. doi:10.1371/journal.pone.0017287.
47. I.Hickie, T.Davenport, D.Wakefield, et al. Infection outcomes study group. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006; 333–575.• Demonstration using convalescent sera that CFS/ME is associated with multiple infectious microbes.
48. J.K.Chia, L.Y.Chia. Chronic chlamydia pneumoniae infection: a treatable cause of chronic fatigue syndrome. Clin Infect Dis. 1999;29:452–453.
49. J.R.Kerr, V.S.Cunniffe, P.Kelleher, et al. Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. Clin Infect Dis. 2003;36:100–106.
50. J.R.Kerr, J.Gough, S.C.Richards, et al. Antibody to parvovirus B19 nonstructural protein is associated with chronic arthralgia in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Gen Virol. 2010;91:893–897.
51. J.K.Chia, A.Y.Chia. Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. J Clin Pathol. 2008;61:43–48.
52. A.Vojdani, P.C.Choppa, C.Tagle, et al. Detection of mycoplasma genus and mycoplasma fermentans by PCR in patients with chronic fatigue syndrome. FEMS Immunol Med Microbiol. 1998;22:355–365.
53. J.Nijs, G.L.Nicolson, P.De Becker, et al. High prevalence of mycoplasma infections among European chronic fatigue syndrome patients. Examination of four mycoplasma species in blood of chronic fatigue syndrome patients. FEMS Immunol Med Microbiol. 2002;34:209–214.
54. E.DeFreitas, B.Hilliard, P.R.Cheney, et al. Retroviral sequences related to human T-?lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome. Proc Natl Acad Sci USA. 1991;88:2922–2926.
55. V.C.Lombardi, F.W.Ruscetti, J.Das Gupta, et al. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science. 2009;326:585–589.
56. S.C.Lo, N.Pripuzova, B.Li, et al. Detection of MLV-related virus gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci USA. 2010;107:15874–15879.
57. H.J.Alter, J.A.Mikovits, W.M.Switzer, et al. A multicenter blinded analysis indicates no association between chronic fatigue syndrome/myalgic encephalomyelitis and either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus. MBio. 2012;3(5).
58. D.Buchwald, P.R.Cheney, D.L.Peterson, et al. A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med. 1992;116:103–113.
59. S.F.Josephs, B.Henry, N.Balachandran, et al. HHV-6 reactivation in chronic fatigue syndrome. Lancet. 1991;337:1346–1347.
60. G.L.Nicolson, R.Gan, J.Haier. Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. Apmis. 2003;111:557–566.
61. E.Barker, S.F.Fujimura, M.B.Fadem, et al. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis. 1994;18(Suppl 1):S136–S141.
62. D.Strayer, V.Scott, W.Carter. Low NK cell activity in Chronic Fatigue Syndrome (CFS) and relationship to symptom severity. J Clin Cell Immunol. 2015;6:4.•• Research assays potentially convertible to clinical reference laboratory biomarker assays for diagnosis and response to rintatolimod.
63. R.J.Suhadolnik, N.L.Reichenbach, P.Hitzges, et al. Upregulation of the 2-?5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis. 1994;18(Suppl 1):S96–S104.
64. R.J.Suhadolnik, N.L.Reichenbach, P.Hitzges, et al. Changes in the 2-?5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome. In Vivo. 1994;8:599–604.•• Demonstration of upregulation of 2ʹ-5ʹA intracellular pathway in CFS/ME and response to rintatolimod.
65. C.R.Snell, J.M.Vanness, D.R.Strayer, et al. Physical performance and prediction of 2-?5A synthetase/RNase L antiviral pathway activity in patients with chronic fatigue syndrome. In Vivo. 2002;16:107–109.
66. S.E.Shetzline, C.Martinand-Mari, N.L.Reichenbach, et al. Structural and functional features of the 37-kDa 2-?5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res. 2002;22:443–456.
67. E.Demettre, L.Bastide, A.D’Haese, et al. Ribonuclease L proteolysis in peripheral blood mononuclear cells of chronic fatigue syndrome patients. J Biol Chem. 2002;277:35746–35751.• Mechanism of 2ʹ-5ʹA dysfunction in CFS/ME.
68. M.Frémont, K.El Bakkouri, F.Vaeyens, et al. 2ʹ,5ʹ-oligoadenylate size is critical to protect RNase L against proteolytic cleavage in chronic fatigue syndrome. Exp Mol Pathol. 2005;78:239–246.•• Research assays potentially convertible to clinical reference laboratory biomarker assays for diagnosis and response to rintatolimod.
69. K.De Meirleir, C.Bisbal, I.Campine, et al. A 37 kDa 2-?5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med. 2000;108:99–105.
70. M.Frémont, F.Vaeyens, C.V.Herst, et al. 37-kilodalton/83-kilodalton RNase L isoform ratio in peripheral blood mononuclear cells: analytical performance and relevance for chronic fatigue syndrome. Clin Diagn Lab Immunol. 2005;12:1259–1260.
71. S.D.Vernon, E.R.Unger, I.M.Dimulescu, et al. Utility of the blood for gene expression profiling and biomarker discovery in chronic fatigue syndrome. Dis Markers. 2002;18:193–199.•• Research assays potentially convertible to clinical reference laboratory biomarker assays for diagnosis and response to rintatolimod.
72. T.Whistler, E.R.Unger, R.Nisenbaum, et al. Integration of gene expression, clinical, and epidemiologic data to characterize chronic fatigue syndrome. J Transl Med. 2003;1:10.
73. T.Whistler, J.F.Jones, E.R.Unger, et al. Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects. BMC Physiol. 2005;5:5.
74. T.Whistler, R.Taylor, R.C.Craddock, et al. Gene expression correlates of unexplained fatigue. Pharmacogenomics. 2006;7(3):395–405.
75. L.Carmel, S.Efroni, P.D.White, et al. Gene expression profile of empirically delineated classes of unexplained chronic fatigue. Pharmacogenomics. 2006;7:375–86.
76. G.Broderick, R.C.Craddock, T.Whistler, et al. Identifying illness parameters in fatiguing syndromes using classical projection methods. Pharmacogenomics. 2006;7:407–419.
77. H.Fang, Q.Xie, R.Boneva, et al. Gene expression profile exploration of a large dataset on chronic fatigue syndrome. Pharmacogenomics. 2006;7(3):429–440.
78. J.Fostel, R.Boneva, A.Lloyd. Exploration of the gene expression correlates of chronic unexplained fatigue using factor analysis. Pharmacogenomics. 2006;7:441–454.
79. R.Powell, J.Ren, G.Lewith, et al. Identification of novel expressed sequences, up-regulated in the leucocytes of chronic fatigue syndrome patients. Clin Exp Allergy. 2003;33:1450–1456.
80. H.Gra¨ns, P.Nilsson. Evengard B gene expression profiling in the chronic fatigue syndrome. J Intern Med. 2005;258:388–390.
81. H.Gra¨ns, M.Nilsson, K.Dahlman-Wright. Evenga° rd B reduced levels of oestrogen receptor beta mRNA in Swedish patients with chronic fatigue syndrome. J Clin Pathol. 2007;60:195–198.
82. J.R.Kerr, B.Burke, R.Petty, et al. Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol. 2008;61:730–739.
83. M.P.Byrd, M.Zamora, R.E.Lloyd. Translation of eukaryotic translation initiation factor 4GI (eIF4GI) proceeds from multiple mRNAs containing a novel cap-dependent internal ribosome entry site (IRES) that is active during poliovirus infection. J Biol Chem. 2005;280:18610–18622.
84. L.Zhang, J.Gough, D.Christmas, et al. Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Pathol. 2010;63:156–164.
85. A.R.Light, L.Bateman, D.Jo, et al. Gene expression alterations at baseline and following moderate exercise in patients with chronic fatigue syndrome and fibromyalgia syndrome. J Intern Med. 2012;271:64–81.
86. A.T.White, A.R.Light, R.W.Hughen, et al. Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls. Psychosom Med. 2012;74:46–54.
87. S.Myhill, N.E.Booth, J.McLaren-Howard. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2009;2:1–16.
88. W.M.Behan, I.A.More, P.O.Behan. Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol. 1991;83:61–65.
89. S.Fulle, P.Mecocci, G.Fanó, et al. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med. 2000;29:1252–1259.
90. H.Kuratsune, K.Yamaguti, M.Takahashi, et al. Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis. 1994;18(Suppl 1):S62–S67.
91. A.V.Plioplys, S.Plioplys. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology. 1995;32:132–138.
92. C.Zhang, A.Baumer, I.R.Mackay, et al. Unusual pattern of mitochondrial DNA deletions in skeletal muscle of an adult human with chronic fatigue syndrome. Hum Mol Genet. 1995;4:751–754.
93. L.Vecchiet, G.Montanari, E.Pizzigallo, et al. Sensory characterization of somatic parietal tissues in humans with chronic fatigue syndrome. Neurosci Lett. 1996 19;208:117–120.
94. D.L.Arnold, P.J.Bore, G.K.Radda, et al. Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a post-viral exhaustion/fatigue syndrome. A 31P nuclear magnetic resonance study. Lancet. 1984;1:1367–1369.
95. K.K.McCully, B.H.Natelson, S.Iotti, et al. Reduced oxidative muscle metabolism in chronic fatigue syndrome. Muscle Nerve. 1996;19:621–625.
96. R.Wong, G.Lopaschuk, G.Zhu, et al. Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest. 1992;102:1716–1722.
97. W.A.Carter, D.R.Strayer Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity. US 8722874 B2: Filing date 3/31/2011/ Award May 13, 2014.